Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Palisade Bio director Robert Baltera Jr. reported open-market purchases of a total of 50,000 shares of common stock. He bought 20,000 shares on July 6, 2026 at a weighted average price of $2.052 per share and 30,000 shares on July 7, 2026 at a weighted average price of $2.0348 per share. The filing notes the trades were executed in multiple transactions within price ranges of $2.04–$2.068 and $2.00–$2.07. Following these purchases, Baltera directly owns 416,904 shares of Palisade Bio common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 50,000 shares ($102,084)
Net Buy
2 txns
Insider
Baltera Robert Jr.
Role
null
Bought
50,000 shs ($102K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 30,000 | $2.0348 | $61K |
| Purchase | Common Stock | 20,000 | $2.052 | $41K |
Holdings After Transaction:
Common Stock — 416,904 shares (Direct, null)
Footnotes (1)
- The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.04 to $2.068. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.00 to $2.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Key Figures
Total shares purchased: 50,000 shares
July 6, 2026 purchase: 20,000 shares at $2.052
July 7, 2026 purchase: 30,000 shares at $2.0348
+3 more
6 metrics
Total shares purchased
50,000 shares
Open-market purchases reported in Form 4
July 6, 2026 purchase
20,000 shares at $2.052
Weighted average price on 2026-07-06
July 7, 2026 purchase
30,000 shares at $2.0348
Weighted average price on 2026-07-07
Post-transaction holdings
416,904 shares
Common stock directly owned after July 7, 2026 trade
Price range July 6, 2026
$2.04–$2.068
Multiple executions; weighted average $2.052
Price range July 7, 2026
$2.00–$2.07
Multiple executions; weighted average $2.0348
Key Terms
open-market purchase, weighted average price, Form 4, Common Stock
4 terms
open-market purchase financial
"transaction_action: "open-market purchase" for each common stock trade"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 regulatory
"INSIDER FILING DATA (Form 4): { "issuerName": "PALISADE BIO, INC.""
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Common Stock financial
""security_title": "Common Stock" for both reported transactions"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider activity did Palisade Bio (PALI) report in this Form 4?
Palisade Bio reported that director Robert Baltera Jr. bought 50,000 common shares in open-market transactions. The purchases occurred on July 6 and 7, 2026, and increased his direct ownership to 416,904 shares of Palisade Bio stock.
What is Robert Baltera Jr.’s total Palisade Bio (PALI) holding after these trades?
After the reported open-market purchases, Robert Baltera Jr. directly owns 416,904 shares of Palisade Bio common stock. This figure, disclosed in the Form 4, reflects his position immediately following the July 7, 2026 transaction.
Were the Palisade Bio (PALI) insider purchases single trades or multiple executions?
The insider purchases were executed as multiple trades. The filing explains that reported prices are weighted averages, with individual executions occurring within price ranges of $2.04–$2.068 and $2.00–$2.07 per share for the two trading days.
Is the Palisade Bio (PALI) director’s transaction classified as a buy or sell?
The transactions are classified as open-market purchases, meaning they are buys. The Form 4 coding and summary show two purchase transactions (code P), totaling 50,000 shares, with no reported sales or other dispositions in this filing.